Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 1
1979 1
1982 1
1983 1
1994 1
1995 2
1999 2
2000 2
2001 6
2002 4
2003 5
2004 3
2005 3
2006 1
2007 3
2008 1
2009 3
2010 4
2011 1
2012 3
2013 5
2014 7
2015 10
2016 4
2017 9
2018 11
2019 8
2020 14
2021 22
2022 32
2023 15

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Ohba A, et al. Among authors: okano n. Future Oncol. 2022 Jun;18(19):2351-2360. doi: 10.2217/fon-2022-0214. Epub 2022 May 5. Future Oncol. 2022. PMID: 35510484 Free article. Review.
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. Among authors: okano n. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Morizane C, et al. Among authors: okano n. Ann Oncol. 2019 Dec 1;30(12):1950-1958. doi: 10.1093/annonc/mdz402. Ann Oncol. 2019. PMID: 31566666 Free article. Clinical Trial.
[Geriatric Oncology].
Maeno S, Nagashima F, Naruge D, Okano N, Kawai K, Kobayashi T, Kitamura H, Furuse J. Maeno S, et al. Among authors: okano n. Gan To Kagaku Ryoho. 2017 Feb;44(2):97-101. Gan To Kagaku Ryoho. 2017. PMID: 28223666 Review. Japanese.
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J. Ueno M, et al. Among authors: okano n. Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621. doi: 10.1016/S2468-1253(19)30086-X. Epub 2019 May 17. Lancet Gastroenterol Hepatol. 2019. PMID: 31109808 Clinical Trial.
Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.
Jogo T, Nakamura Y, Shitara K, Bando H, Yasui H, Esaki T, Terazawa T, Satoh T, Shinozaki E, Nishina T, Sunakawa Y, Komatsu Y, Hara H, Oki E, Matsuhashi N, Ohta T, Kato T, Ohtsubo K, Kawakami T, Okano N, Yamamoto Y, Yamada T, Tsuji A, Odegaard JI, Taniguchi H, Doi T, Fujii S, Yoshino T. Jogo T, et al. Among authors: okano n. Clin Cancer Res. 2021 Oct 15;27(20):5619-5627. doi: 10.1158/1078-0432.CCR-21-1414. Epub 2021 Aug 10. Clin Cancer Res. 2021. PMID: 34376535 Free PMC article.
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, Ishii H, Mizusawa J, Katayama H, Kataoka T, Okusaka T, Ikeda M, Sasahira N, Miwa H, Mizukoshi E, Okano N, Mizuno N, Yamamoto T, Komatsu Y, Todaka A, Kamata K, Furukawa M, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Fukuda H, Ueno M, Furuse J; Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG). Ozaka M, et al. Among authors: okano n. Eur J Cancer. 2023 Mar;181:135-144. doi: 10.1016/j.ejca.2022.12.014. Epub 2022 Dec 27. Eur J Cancer. 2023. PMID: 36652891 Free article. Clinical Trial.
Routine biliary cannulation techniques.
Okano N, Igarashi Y, Ito K. Okano N, et al. Dig Endosc. 2016 Apr;28 Suppl 1:103-4. doi: 10.1111/den.12619. Dig Endosc. 2016. PMID: 26845384 No abstract available.
166 results